Correction: Colorectal Cancer Stem Cells Are Enriched in Xenogeneic Tumors Following Chemotherapy

Scott J. Dylla, Lucia Beviglia, Inkyung Park, Cécile Chartier, Janak Raval, Lucy Ngan, Kellie Pickell, Jorge Aguilar, Sasha Lazetic, Stephanie Smith‐Berdan,

PLoS ONE · 2008 · 42 citations · 31 references

DOIFull text

Open access

Concepts

Abstract

Background: Patients generally die of cancer after the failure of current therapies to eliminate residual disease. A subpopulation of tumor cells, termed cancer stem cells (CSC), appears uniquely able to fuel the growth of phenotypically and histologically diverse tumors. It has been proposed, therefore, that failure to effectively treat cancer may in part be due to preferential resistance of these CSC to chemotherapeutic agents. The subpopulation of human colorectal tumor cells with an ESA + CD44 + phenotype are uniquely responsible for tumorigenesis and have the capacity to generate heterogeneous tumors in a xenograft setting (i.e. CoCSC). We hypothesized that if non-tumorigenic cells are more susceptible to chemotherapeutic agents, then residual tumors might be expected to contain a higher frequency of CoCSC.

References

31